Dosing and uses of Ocuflox (ofloxacin ophthalmic)
Adult dosage forms and strengths
ophthalmic solution
- 0.3%
Bacterial Conjunctivitis
Days 1-2: 1-2 gtt in affected eye q2-4hr, THEn
Days 3-7: 1-2 gtt four times daily
Corneal Ulcer
Days 1-2: 1-2 gtt q30min while awake (WA), awaken 4-6 hours after retiring
Days 3-7: 1-2 gtt q1hr while awake
Days 7-9: 1-2 gtt four times daily until clinical cure
Pediatric dosage forms and strengths
ophthalmic solution
- 0.3%
Bacterial Conjunctivitis
< 1 year
- Not recommended
> 1 year
- Day 1-2: 1-2 gtt in affected eye q2-4hr, THEN
- Day 3-7: 1-2 gtt four times daily
Corneal Ulcer
< 1 year
- Not recommended
> 1 year
- Days 1-2: 1-2 gtt q30min while awake (WA), awaken 4-6 hours after retiring
- Days 3-7: 1-2 gtt q1hr while awake
- Days 7-9: 1-2 gtt four times daily until clinical cure
Ocuflox (ofloxacin ophthalmic) adverse (side) effects
Frequency not defined
Transient ocular burning or discomfort following instillation of the solution
Conjunctival hyperemia
Chemical conjunctivitis/keratitis
Foreign body sensation
Blurred vision
Periocular/facial edema
Eye pain
Photophobia
Pruritus
Stinging
Tearing
Dryness
Hemorrhagic conjunctivitis with palpebral edema (rare)
Warnings
Contraindications
Hypersensitivity to quinolones or other components in product
Cautions
May result in overgrowth of nonsusceptible organisms, including fungi
Careful monitoring, including slit-lamp biomicroscopy and fluorescein staining when appropriate may be necessary
Not for subconjunctival injection
Pregnancy and lactation
Pregnancy category: C
Lactation: Not known if distributed into milk; discontinue breastfeeding or drug
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Ocuflox (ofloxacin ophthalmic)
Mechanism of action
BactericidaL
Inhibits DNA topoisomerase (ATP-hydrolyzing), a type II DNA topoisomerase commonly referred to as DNA-gyrase, in susceptible organisms
Pharmacokinetics
Absorption: Minimal systemic absorption with ophthalmic use
Excretion: Urine
